LY75 Overview
Molecule Name
Lymphocyte antigen 75
Synonyms
LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs0
Highest Development StagePhase 1 Clinical
Target Synonym
LY75，CD205，Lymphocyte Antigen 75，C-Type Lectin Domain Family 13 Member B，CLEC13B，DEC-205，CD205 Antigen，Gp200-MR6，Ly-75
Background
lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.
LY75 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Oberotatug ravtansine | OBT-076; MEN1309/OBT076; MEN-1309 | Phase 1 Clinical | Menarini, Oxford Biotherapeutics Ltd | Carcinoma, Adenoid Cystic; Head and Neck Neoplasms; Lymphoma, Non-Hodgkin; Solid tumours | Details |